7 Residual cancer cells present beyond these times are likely to be resistant to treatment. Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability ...

"While we await results from ongoing prospective trials, our data suggest that treatment decisions should consider both the prior history of CDK4/6i benefit and the pattern of metastatic spread." ...